Jonathan Wosen from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 8 days ago Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago Study paints clearer picture of disadvantaged leukemia patients’ struggle to get bone marrow transplants - 12 days ago Sanofi advances a drug for a rare, platelet-destroying disease - 13 days ago STAT+: Trump’s return raises concerns about funding cuts and politicization at the NIH - about 1 month ago STAT+: Exact Sciences wins FDA approval for improved stool-based colon cancer test - 3 months ago STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 3 months ago STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending - 3 months ago STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - 3 months ago Study of gender-affirming care reveals immune system sex differences - 4 months ago STAT+: Gene therapy pioneer Jim Wilson believes he can commercialize rare-disease drugs in a tough climate - 4 months ago Teamwork is good for science — but maybe not for young researchers’ careers - 4 months ago STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more - 5 months ago Expansive new study points to distinct brain networks linked to sex and gender - 5 months ago STAT+: Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer’s drug - 6 months ago STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test - 7 months ago STAT+: About half of cancer drugs given accelerated approval don’t show improved survival or quality of life - 9 months ago STAT+: Cancer is rising among the young. Study suggests it’s because their cells are aging faster - 9 months ago STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves - 10 months ago STAT+: A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit - 11 months ago STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi - 12 months ago Allen Institute CEO Rui Costa on mapping the brain and paying early-career scientists decent salaries - 12 months ago NIH panel calls for fewer, better-paid postdocs in bid to halt loss of scientists to industry - about 1 year ago STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study - about 1 year ago STAT+: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease - about 1 year ago STAT+: Late-stage trial supports broader use of Darzalex, blockbuster J&J multiple myeloma drug - about 1 year ago STAT+: Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers - about 1 year ago STAT+: Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH - about 1 year ago STAT+: With biotech in a slump, the industry’s job market is upside down - about 1 year ago Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire - about 1 year ago STAT+: Life scientists’ flight to biotech labs stalls important academic research - about 1 year ago Rats have an imagination, too, researchers show with brain implants - about 1 year ago STAT+: FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation - about 1 year ago STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs - about 1 year ago STAT+: Cell and gene therapy CEOs share survival strategies amid biotech slump - about 1 year ago STAT+: Scientists have mapped the human brain in unprecedented detail. They’re just getting started - about 1 year ago STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug - about 1 year ago STAT+: Failed biotech gives a rare peek inside the tough breaks — and tough choices — that led to its demise - about 1 year ago STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard - about 1 year ago STAT+: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’ - over 1 year ago
2	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 8 days ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago Sanofi advances a drug for a rare, platelet-destroying disease - 13 days ago STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study - about 1 year ago
4	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test - 7 months ago STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves - 10 months ago STAT+: A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit - 11 months ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago
6	Usha Lee McFarling STAT News	STAT+: Trump’s return raises concerns about funding cuts and politicization at the NIH - about 1 month ago
7	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	STAT+: With biotech in a slump, the industry’s job market is upside down - about 1 year ago